Literature DB >> 26077103

Oscillatory mTOR inhibition and Treg increase in kidney transplantation.

M Sabbatini1, G Ruggiero2, A T Palatucci3,4, V Rubino2, S Federico1, A Giovazzino2,4, L Apicella1, M Santopaolo5, G Matarese6,7, M Galgani8, G Terrazzano2,4.   

Abstract

Intracellular metabolic pathways dependent upon the mammalian target of rapamycin (mTOR) play a key role in immune-tolerance control. In this study, we focused on long-term mTOR-dependent immune-modulating effects in kidney transplant recipients undergoing conversion from calcineurin inhibitors (CNI) to mTOR inhibitors (everolimus) in a 1-year follow-up. The conversion to everolimus is associated with a decrease of neutrophils and of CD8(+) T cells. In addition, we observed a reduced production of interferon (IFN)-γ by CD8(+) T cells and of interleukin (IL)-17 by CD4(+) T lymphocytes. An increase in CD4(+) CD25(+) forkhead box protein 3 (FoxP3)(+) [regulatory T cell [(Treg)] numbers was also seen. Treg increase correlated with a higher proliferation rate of this regulatory subpopulation when compared with the CD4(+) FoxP3(-) effector counterpart. Basal phosphorylation level of S6 kinase, a major mTOR-dependent molecular target, was substantially maintained in patients treated with everolimus. Moreover, oscillations in serum concentration of everolimus were associated with changes in basal and activation-dependent S6 kinase phosphorylation of CD4(+) and CD8(+) T cells. Indeed, T cell receptor (TCR) triggering was observed to induce significantly higher S6 kinase phosphorylation in the presence of lower everolimus serum concentrations. These results unveil the complex mTOR-dependent immune-metabolic network leading to long-term immune-modulation and might have relevance for novel therapeutic settings in kidney transplants.
© 2015 British Society for Immunology.

Entities:  

Keywords:  everolimus; immunosuppression; kidney transplants; mTOR

Mesh:

Substances:

Year:  2015        PMID: 26077103      PMCID: PMC4608513          DOI: 10.1111/cei.12669

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  48 in total

Review 1.  Chemokines: directing leukocyte infiltration into allografts.

Authors:  Tarek el-Sawy; Nader M Fahmy; Robert L Fairchild
Journal:  Curr Opin Immunol       Date:  2002-10       Impact factor: 7.486

2.  Actively acquired tolerance of foreign cells.

Authors:  R E BILLINGHAM; L BRENT; P B MEDAWAR
Journal:  Nature       Date:  1953-10-03       Impact factor: 49.962

3.  Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era.

Authors:  Herwig-Ulf Meier-Kriesche; Jesse D Schold; Titte R Srinivas; Bruce Kaplan
Journal:  Am J Transplant       Date:  2004-03       Impact factor: 8.086

Review 4.  Development of everolimus, a novel oral mTOR inhibitor, across a spectrum of diseases.

Authors:  David Lebwohl; Ozlem Anak; Tarek Sahmoud; Judith Klimovsky; Ingrid Elmroth; Tomas Haas; Joseph Posluszny; Stephen Saletan; William Berg
Journal:  Ann N Y Acad Sci       Date:  2013-05-09       Impact factor: 5.691

Review 5.  Meta-analysis of calcineurin-inhibitor-sparing regimens in kidney transplantation.

Authors:  Adnan Sharif; Shazia Shabir; Sourabh Chand; Paul Cockwell; Simon Ball; Richard Borrows
Journal:  J Am Soc Nephrol       Date:  2011-09-23       Impact factor: 10.121

6.  Immunosuppressive drugs on inducing Ag-specific CD4(+)CD25(+)Foxp3(+) Treg cells during immune response in vivo.

Authors:  Tingting Wu; Lianjun Zhang; Kerui Xu; Chenming Sun; Tong Lei; Jianxia Peng; Guangwei Liu; Ruoyu Wang; Yong Zhao
Journal:  Transpl Immunol       Date:  2012-05-14       Impact factor: 1.708

7.  SDZ RAD, a new rapamycin derivative: pharmacological properties in vitro and in vivo.

Authors:  W Schuler; R Sedrani; S Cottens; B Häberlin; M Schulz; H J Schuurman; G Zenke; H G Zerwes; M H Schreier
Journal:  Transplantation       Date:  1997-07-15       Impact factor: 4.939

8.  Rapamycin for treatment of chronic allograft nephropathy in renal transplant patients.

Authors:  Giovanni Stallone; Barbara Infante; Antonio Schena; Michele Battaglia; Pasquale Ditonno; Antonia Loverre; Loreto Gesualdo; Francesco Paolo Schena; Giuseppe Grandaliano
Journal:  J Am Soc Nephrol       Date:  2005-10-19       Impact factor: 10.121

9.  PLD1 regulates mTOR signaling and mediates Cdc42 activation of S6K1.

Authors:  Yimin Fang; In-Hyun Park; Ai-Luen Wu; Guangwei Du; Ping Huang; Michael A Frohman; Stephanie J Walker; H Alex Brown; Jie Chen
Journal:  Curr Biol       Date:  2003-12-02       Impact factor: 10.834

10.  Homeostasis-stimulated proliferation drives naive T cells to differentiate directly into memory T cells.

Authors:  B K Cho; V P Rao; Q Ge; H N Eisen; J Chen
Journal:  J Exp Med       Date:  2000-08-21       Impact factor: 14.307

View more
  15 in total

Review 1.  Role of Metabolism in the Immunobiology of Regulatory T Cells.

Authors:  Mario Galgani; Veronica De Rosa; Antonio La Cava; Giuseppe Matarese
Journal:  J Immunol       Date:  2016-10-01       Impact factor: 5.422

Review 2.  Roles of mTOR complexes in the kidney: implications for renal disease and transplantation.

Authors:  Daniel Fantus; Natasha M Rogers; Florian Grahammer; Tobias B Huber; Angus W Thomson
Journal:  Nat Rev Nephrol       Date:  2016-08-01       Impact factor: 28.314

3.  Metabolic pressure and the breach of immunological self-tolerance.

Authors:  Veronica De Rosa; Antonio La Cava; Giuseppe Matarese
Journal:  Nat Immunol       Date:  2017-10-18       Impact factor: 25.606

Review 4.  The role of lipid metabolism in shaping the expansion and the function of regulatory T cells.

Authors:  Alessandra Pinzon Grimaldos; Simone Bini; Ilenia Pacella; Alessandra Rossi; Alessia Di Costanzo; Ilenia Minicocci; Laura D'Erasmo; Marcello Arca; Silvia Piconese
Journal:  Clin Exp Immunol       Date:  2022-06-11       Impact factor: 5.732

5.  Immunoregulatory Effects of Everolimus on In Vitro Alloimmune Responses.

Authors:  Josh Levitsky; Joshua Miller; Xuemei Huang; Lorenzo Gallon; Joseph R Leventhal; James M Mathew
Journal:  PLoS One       Date:  2016-06-08       Impact factor: 3.240

6.  Effects of mTOR inhibition on cardiac and adipose tissue pathology and glucose metabolism in rats with metabolic syndrome.

Authors:  Ayako Uchinaka; Mamoru Yoneda; Yuichiro Yamada; Toyoaki Murohara; Kohzo Nagata
Journal:  Pharmacol Res Perspect       Date:  2017-08

7.  An Open Question: Is It Rational to Inhibit the mTor-Dependent Pathway as COVID-19 Therapy?

Authors:  Giuseppe Terrazzano; Valentina Rubino; Anna Teresa Palatucci; Angela Giovazzino; Flavia Carriero; Giuseppina Ruggiero
Journal:  Front Pharmacol       Date:  2020-05-29       Impact factor: 5.810

8.  Early Everolimus Initiation Fails to Counteract the Cytotoxic Response Mediated by CD8+ T and NK Cells in Heart Transplant Patients.

Authors:  Beatriz Díaz-Molina; Paula Diaz-Bulnes; Reyes Carvajal Palao; Maria José Bernardo; Ramón M Rodriguez; Viviana Corte-Iglesias; Cesar Moris de la Tassa; Jose Luis Lambert; Beatriz Suarez-Alvarez
Journal:  Front Immunol       Date:  2018-09-26       Impact factor: 7.561

Review 9.  Inducing and Administering Tregs to Treat Human Disease.

Authors:  Ana Luisa Perdigoto; Lucienne Chatenoud; Jeffrey A Bluestone; Kevan C Herold
Journal:  Front Immunol       Date:  2016-01-22       Impact factor: 7.561

10.  Long-Term Redistribution of Peripheral Lymphocyte Subpopulations after Switching from Calcineurin to mTOR Inhibitors in Kidney Transplant Recipients.

Authors:  Laura Llinàs-Mallol; Dolores Redondo-Pachón; Dàlia Raïch-Regué; María José Pérez-Sáez; José Yélamos; Xavier Duran; Anna Faura; Miguel López-Botet; Julio Pascual; Marta Crespo
Journal:  J Clin Med       Date:  2020-04-11       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.